[Redding, California] – Meticulous Research®, a leading global market research firm, has unveiled its latest comprehensive analysis titled “Pharmaceutical Contract Development & Manufacturing Market Size, Share, Forecast, & Trends Analysis by Service(Manufacturing [API, FDF {Parenteral, Injectable, Tablet, Capsule, Oral Liquid, Biologics}], Drug Development) End User – Global Forecast to 2031.” According to the report, the pharmaceutical contract development and manufacturing market is poised to reach a significant milestone of $261.57 billion by 2031, registering a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031.
1. Market Growth Catalysts
The growth trajectory of the pharmaceutical contract development and manufacturing market is primarily fueled by the pharmaceutical industry’s increasing complexity, alongside a growing reliance on cutting-edge manufacturing technologies. The surge in pharmaceutical R&D investments, the expiration of critical patents, and the escalating demand for generic medicines and biologics are additional key drivers. However, challenges such as supply chain disruptions and stringent regulatory frameworks are creating headwinds for the market.
Download Sample Report Here : https://www.meticulousresearch.com/download–samplereport/cp_id=5171
2. Emerging Opportunities and Challenges
As the market evolves, it presents notable opportunities, particularly in the burgeoning sectors of cell therapies, gene therapies, and personalized medicine. The growth in high-potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets further underscores the potential for expansion. However, the market also faces significant challenges, including intellectual property risks and a shortage of skilled professionals required to navigate the complexities of pharmaceutical manufacturing.
3. Key Industry Players
The pharmaceutical contract development and manufacturing landscape is dominated by several key players, including:
- Lonza Group Ltd. (Switzerland)
- Catalent Inc. (U.S.)
- Patheon (a subsidiary of Thermo Fisher Scientific Inc., U.S.)
- Recipharm AB (Sweden)
- C.H. Boehringer Sohn AG & CO. KG. (Germany)
- Aurobindo Pharma Ltd. (India)
- Jubilant Pharmova Limited (India)
- Fareva SA (Luxembourg)
- Vetter Pharma International GmbH (Germany)
- Aenova Group (Germany)
- WuXi Biologics Inc. (China)
- Piramal Enterprises Limited (India)
- Almac Group (U.K.)
- Fabbrica Italiana Sintetici S.p.A. (F.I.S., Italy)
- Samsung Biologics Co., Ltd. (South Korea)
- Cambrex Corporation (U.S.)
- Siegfried Holdings AG (Switzerland)
- FUJIFILM Diosynth Biotechnologies (Japan)
- Curia Global, Inc. (U.S.)
Quick Buy: https://www.meticulousresearch.com/Checkout/67156803
4. Market Segmentation and Future Outlook
The report categorizes the pharmaceutical contract development and manufacturing market by type, end user, and geography. Notably, the biologics manufacturing services segment is expected to experience a higher CAGR of 11.1% during the forecast period. This segment is further subdivided into finished dosage form (FDF) manufacturing services and active pharmaceutical ingredient (API) manufacturing services. The FDF category, driven by the rising importance of biologics and their intricate manufacturing processes, is anticipated to lead the growth.
Among end users, large pharmaceutical companies are projected to dominate the market, accounting for 42.3% of the market share by 2024. The increasing complexity of drug research and the high costs associated with facility maintenance have made contract manufacturers indispensable to large biotech and pharmaceutical companies. Additionally, with the expiration of many drug patents, these companies increasingly rely on contract development firms to bring generic versions of their drugs to market.
5 Regional Insights
Geographically, North America is poised to maintain its leadership in the pharmaceutical contract development and manufacturing market, with an estimated 44.3% market share by 2024. This dominance is supported by a diversified product pipeline, emerging therapies, shifting customer demands, and an increasing focus on biologics and generic drugs. North America also benefits from a large production base for APIs, advanced manufacturing capabilities, and the presence of major pharmaceutical companies.
Request Sample Report Here: https://www.meticulousresearch.com/request–samplereport/cp_id=5171
Key Questions Addressed in the Report
- What are the high-growth market segments by type, end user, and region/country?
- What are the historical market sizes and forecasts for 2024–2031?
- What are the primary drivers, restraints, opportunities, and challenges in the market?
- Who are the major players and market leaders?
- What recent developments and strategies have shaped the competitive landscape?
- Which regions/countries are experiencing the highest growth?
Contact Information
Meticulous Research®
Email: sales@meticulousresearch.com
Phone: +1-646-781-8004
LinkedIn: Connect with us on LinkedIn
